Law360, New York (May 21, 2012, 8:49 PM ET) -- A clinical reviewer for the U.S. Food and Drug Administration recommended that Johnson & Johnson and Bayer AG blood thinner Xarelto be approved for patients with acute coronary syndrome, despite concerns from at least one other medical expert, according to FDA briefs made public Monday.
Dr. Karen A. Hicks said in her review that studies have shown the drug will reduce the risk of cardiovascular death, heart attacks and strokes in people with ACS — which occurs when a blood clot forms inside a coronary artery...
FDA Reviewer Backs J&J's Xarelto For Heart Condition
To view the full article, take a free trial now.
